Viridian Therapeutics, Inc.\DE
Viridian Therapeutics, Inc.\DE (VRDN): 7 pipeline candidates · 3 upcoming catalysts · ~19 mo cash runway · 5 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
18.5 months
D/E 0.24 · 0% dilution
Lead: Phase 3
7 candidates
3 upcoming, next in ~105d
1 buy · 1 sell (180d)
A transparent, data-derived signal for Viridian Therapeutics, Inc.\DEacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$1.8B
Cash
$176.3M
Quarterly Burn
$119.7M
Runway
18.5 mo
Revenue
$141K
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (7 candidates)
| Drug | Phase |
|---|---|
| Anti-TSHR candidate | Preclinical |
| elegrobart | Phase 3 |
| veligrotug | Phase 3 |
| VRDN-001 | Phase 3 |
| VRDN-003 | Phase 3 |
| VRDN-006 | Phase 3 |
| VRDN-008 | Phase 3 |
Upcoming Catalysts (3)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
222
Total value held
$1.93B
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 15,379,377 | $300.8M |
| vanguard capital management llc | 8,334,402 | $163.0M |
| blackrock, inc. | 7,831,475 | $153.2M |
| state street corp | 4,672,885 | $91.4M |
| wellington management group llp | 3,078,554 | $60.2M |
| citadel advisors llc | 2,382,934 | $46.6M |
| perceptive advisors llc | 2,341,658 | $45.8M |
| kynam capital management, lp | 2,341,652 | $45.8M |
| geode capital management, llc | 2,333,213 | $45.6M |
| balyasny asset management l.p. | 2,315,957 | $45.3M |
Showing top 10 of 222 institutional holders of Viridian Therapeutics, Inc.\DE. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Viridian Therapeutics, Inc.\DE's pipeline?
Viridian Therapeutics, Inc.\DE (VRDN) has 7 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Viridian Therapeutics, Inc.\DE's lead drug candidate?
Viridian Therapeutics, Inc.\DE's most advanced tracked candidate is Anti-TSHR candidate (Preclinical) for Graves' disease and Thyroid Eye Disease (TED).
What is Viridian Therapeutics, Inc.\DE's next catalyst?
Viridian Therapeutics, Inc.\DE's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Randomized, Double-masked, Controlled, Safety and Tolerability Study of VRDN-003 in Participants W" — expected October 1, 2026.
What is Viridian Therapeutics, Inc.\DE's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Viridian Therapeutics, Inc.\DE has approximately 18.5 months of cash runway.
What is Viridian Therapeutics, Inc.\DE's market capitalization?
Viridian Therapeutics, Inc.\DE's market capitalization is approximately $1.8B.
Get the full picture on Viridian Therapeutics, Inc.\DE
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.